Expediting Drug Approval in the US
This article was originally published in SRA
Executive Summary
Regulatory changes in the US such as the risk evaluation and mitigation strategies required by the Food and Drug Administration Amendments Act of 2007 are having a profound effect on drug review times and on review outcomes, a white paper from PAREXEL Consulting has revealed1.